Immunovant Inc’s filing revealed that its Officer WILLIAM MACIAS acquired Company’s shares for reported $1.25 million on Jun 03 ’25. In the deal valued at $15.61 per share,80,000 shares were bought.
Then, GEORGE V MIGAUSKY bought 21,812 shares, generating $318,047 in total proceeds.
Before that, GEORGE V MIGAUSKY bought 28,188 shares. Immunovant Inc shares valued at $410,908 were divested by the Former Director at a price of $14.58 per share.
Jefferies initiated its Immunovant Inc [IMVT] rating to a Hold in a research note published on March 03, 2025; the price target was $20. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in early January from “an Outperform” to “a Peer perform”. Oppenheimer maintained its rating on October 09, 2024. It rated IMVT as “an Outperform”.
Price Performance Review of IMVT
On Friday, Immunovant Inc [NASDAQ:IMVT] saw its stock jump 4.68% to $16.77. Over the last five days, the stock has gained 12.93%. Immunovant Inc shares have fallen nearly -32.30% since the year began. Nevertheless, the stocks have fallen -33.53% over the past one year. While a 52-week high of $34.47 was reached on 01/02/25, a 52-week low of $12.72 was recorded on 04/09/25. SMA at 50 days reached $15.06, while 200 days put it at $23.24.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 16.32, which if violated will result in even more drops to 15.87. On the upside, there is a resistance level at 17.16. A further resistance level may holdings at 17.55. The Relative Strength Index (RSI) on the 14-day chart is 65.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.03, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 9.97%. Stochastics %K at 87.23% indicates the stock is a selling.
The most recent change occurred on March 28, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
